HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.
Dr. Fewell possesses more than 10 years management and scientific leadership experience in the biotechnology industry and has served at EGEN since 2003 as Director of Biology and Pharmacology. During his tenure at EGEN he has helped lead the development and testing of proprietary discovery and development initiatives contributing to a strong intellectual property position. He has been instrumental in building EGEN's research and development team and has helped foster important industry collaborations. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at Cincinnati's Children Hospital. During his active career in research and development, Dr. Fewell has authored numerous scientific publications and is a named inventor on several patents and patent applications in the area of non-viral gene and siRNA delivery.
About EGEN, Inc.
EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.
|SOURCE EGEN, Inc.|
Copyright©2009 PR Newswire.
All rights reserved